Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Autor:	Lam K; Department of Neurology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, California, USA., Eldred BSC; Department of Neurology, University of California, Los Angeles, California, USA., Kevan B; Department of Neurology, University of California, Los Angeles, California, USA., Pianka S; Department of Neurology, University of California, Los Angeles, California, USA., Eldred BA; Department of Strategic Communications, Sonoma State University, Rohnert Park, California, USA., Zapanta Rinonos S; Department of Neurology, University of California, Los Angeles, California, USA., Yong WH; Department of Pathology and Laboratory Medicine, University of California, Irvine, California, USA., Liau LM; Department of Neurosurgery, University of California, Los Angeles, California, USA., Nghiemphu PL; Department of Neurology, University of California, Los Angeles, California, USA., Cloughesy TF; Department of Neurology, University of California, Los Angeles, California, USA., Green RM; Department of Neurology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, California, USA., Lai A; Department of Neurology, University of California, Los Angeles, California, USA.
Jazyk:	angličtina
Zdroj:	Neuro-oncology advances [Neurooncol Adv] 2022 Mar 01; Vol. 4 (1), pp. vdac030. Date of Electronic Publication: 2022 Mar 01 (Print Publication: 2022).
DOI:	10.1093/noajnl/vdac030
Abstrakt:	Background: Patients with isocitrate dehydrogenase ( IDH ) mutant gliomas have been associated with longer survival time than those that are IDH wild-type. Previous studies have shown the prognostic value of O 6 -methylguanine-DNA methyltransferase ( MGMT ) promoter methylation for glioblastoma multiforme (GBM), which are predominantly IDH wild-type. Little is known of the prognostic value of MGMT methylation status for IDH mutant gliomas. Methods: We retrospectively identified IDH mutant gliomas patients between 2011 and 2020 that were tested for MGMT promoter methylation. We generated Kaplan-Meier estimator curves and performed Cox proportional hazard models for overall survival (OS) and progression-free survival (PFS) to compare the outcomes of MGMT promoter methylated versus MGMT unmethylated patients. Results: Of 419 IDH mutant gliomas with MGMT promoter methylation testing, we identified 54 GBMs, 223 astrocytomas, and 142 oligodendrogliomas. 62.3% patients had MGMT methylated tumors while 37.7% were MGMT unmethylated. On Kaplan-Meier analysis, median OS for all MGMT methylated patients was 17.7 years and 14.6 years for unmethylated patients. Median PFS for all MGMT methylated patients was 7.0 years and for unmethylated patients 5.2 years. After univariate subgroup analysis, MGMT methylation is only prognostic for OS and PFS in GBM, and for OS in anaplastic oligodendroglioma and anaplastic oligodendroglioma for OS. In multivariate analysis, MGMT unmethylated GBM patients carry a higher risk of death (HR 7.72, 95% CI 2.10-28.33) and recurrence (HR 3.85, 95% CI 1.35-10.96). Conclusions: MGMT promoter methylation is associated with better OS and PFS for IDH mutant GBM. MGMT promoter methylation testing for other IDH mutant glioma subtypes may not provide additional information on prognostication. (© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu